drugset / Trial / NCT00028431
Novel Adjuvants for Peptide-Based Melanoma Vaccines
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
Timeline
- Start
- 2001-08
- Primary completion
- 2003-01
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | MART-1:26-35(27L) | Peptide | 0.5 mg | — |
| Subject | gp100:209-217(210M) | Peptide | 0.5 mg | — |
| Subject | tyrosinase 368-376 (370D) | Peptide | 0.5 mg | — |